The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. Academic Article uri icon

Overview

abstract

  • The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

publication date

  • August 7, 2016

Research

keywords

  • Adrenal Cortex Hormones
  • Immunologic Factors
  • Infections
  • Infliximab
  • Melanoma

Identity

PubMed Central ID

  • PMC5106605

Scopus Document Identifier

  • 85014932328

Digital Object Identifier (DOI)

  • 10.1093/cid/ciw539

PubMed ID

  • 27501841

Additional Document Info

volume

  • 63

issue

  • 11